血凝酶与拓扑替康联合灌注化疗癌血性胸腔积液的疗效观察  

The chest perfusion blood clots enzyme and the topological metastatic cancer chemotherapy for health effect,hemorrhagic pleural effusion and adverse reaction of the quality of survival

作　　者：王兴远[1] 周伟[1] 江波[1] 李程[1] 王颖[1] 应伟[1] 

机构地区：[1]广安市人民医院肿瘤科,四川广东638001

出　　处：《西部医学》2012年第2期317-318,共2页Medical Journal of West China

基　　金：四川省卫生厅科研课题(编号080133)

摘　　要：目的评价胸腔灌注血凝酶与拓扑替康治疗癌性血性胸腔积液的疗效、毒副反应及对患者生存质量的影响。方法对29例癌性血性胸腔积液患者使用中心静脉导管引流联合血凝酶与拓扑替康针腔内灌注化疗。结果 29例经治疗2～4次后,完全缓解10例,部分缓解15例,总有效率86.2%,且无明显毒副反应。结论中心静脉导管引流联合血凝酶与拓扑替康腔内灌注化疗,对癌性血性胸腔积液治疗效果良好。Objective To evaluate the chest perfusion blood clots enzyme and the topological metastatic cancer chemotherapy for health effect,hemorrhagic pleural effusion and adverse reaction of the quality of survival.Methods In 29 patients after breast cancer diagnosis for water cytology of hemorrhagic pleural effusion,and 38~71 year old age,using central venous catheter drainage joint hemocoagulase atrox and topology for kang needle chamber infusion chemotherapy.Results The treatment of 29 patients after 2~4 times,10 cases,complete remission of 4 cases failure;the total effective 86.2% respectively,with no obvious adverse reaction.Conclusion Central venous catheter drainage joint hemocoagulase atrox and topotecan for kang cavity infusion chemoembolization of cancerous hemorrhagic pleural effusion therapeutic effect.

关 键 词：中心静脉导管 癌性血性胸腔积液 血凝酶 拓扑替康 胸腔灌注化疗 

分 类 号：R561.5[医药卫生—呼吸系统]